EGFR and lung adenocarcinoma: After phase I trials confirmed activity of afatinib in EGFR mutation-positive NSCLC [98,99], the phase II LUX-Lung 2 trial assessed the efficacy of afatinib in patients with lung adenocarcinoma with activating EGFR mutations (exon 18–21) [91].